Meeting
2020 ASCO Virtual Scientific Program
Population-adjusted indirect treatment comparison (PAITC) of maintenance PARP inhibitor (PARPi) with or without bevacizumab versus bevacizumab in women with newly diagnosed ovarian cancer (OC).
Authors
Robert Hettle
AstraZeneca, Cambridge, United Kingdom
Robert Hettle , Charles McCrea , Chee Khoon Lee , Richard Davidson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02477644 and NCT02655016
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6052)
DOI
10.1200/JCO.2020.38.15_suppl.6052
Abstract #
6052
Poster Bd #
223
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.
First Author: Florian Heitz
Poster
2019 ASCO Annual Meeting
DUO-O: A randomized Phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.
First Author: Philipp Harter
Poster
2024 ASCO Annual Meeting
Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS).
First Author: Myong Cheol Lim
Poster
2022 ASCO Annual Meeting
Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644).
First Author: Jean Emmanuel Kurtz